Nationwide Study on the Cervical Cancer Screening Pathway in Estonia
International Journal of Cancer · 15.08.2026 · 159 (4) · 883-895
DOI: 10.1002/ijc.70466 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 09.04.2026. Verfasst von Aleksandra Šavrova und 6 weiteren Autor:innen. Beteiligte Einrichtung: North Estonia Medical Centre, Women's Clinic, Tallinn, Estonia. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Estonian Research Council, Eesti Teadusagentuur.
Abstract (Originalsprache)
Effective cervical cancer screening and progress toward WHO elimination targets depend on complete follow‐up for women with positive primary screening tests. However, real‐world data on this critical step in hrHPV‐based screening programs in Eastern Europe are scarce. We conducted a nationwide, population‐based retrospective cohort study in Estonia, analyzing records from the Estonian Health Insurance Fund and Population Register. We included 44,282 women aged 30–65 who were invited to hrHPV‐based screening between January 1, 2021, and December 31, 2022, with follow‐up through March 31, 2024. Screening attendance was 45.7% ( n = 20,242; 95% CI: 45.2%–46.2%), with 8.0% ( n = 1615; 95% CI: 7.6%–8.4%) testing hrHPV‐positive. A substantial loss to follow‐up was observed: 57.7% of hrHPV‐positive women did not undergo repeat hrHPV testing, colposcopy, or any post‐colposcopy care within 12 months. Among those referred for further diagnosis, colposcopy was performed in 77.9% within 6 months. Treatment for High‐Grade Squamous Intraepithelial Lesion (HSIL) cases was high (85.5%; n = 124; 95% CI: 78.7%–90.5%), mostly within 3 months. Predictors of lower follow‐up adherence included older age and residence in South Estonia. Suboptimal screening uptake and high loss to follow‐up among hrHPV‐positive women are significant barriers to effective cervical cancer prevention in Estonia. These challenges mirror those seen in many organized screening programs globally. Prioritizing strategies to enhance follow‐up adherence is critical for timely diagnosis and treatment, ultimately accelerating global efforts toward cervical cancer elimination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- North Estonia Medical Centre, Women's Clinic, Tallinn, Estonia.
- Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
- National Institute for Health Development, Tallinn, Estonia.
- Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
ORCID-Profile: Aleksandra Šavrova, Anna Tisler, Kaire Innos
Förderung
- Estonian Research Council
- Eesti Teadusagentuur
Zitieren
APA
Šavrova, A., Jakoby, H., Tisler, A., Innos, K., Maiväli, Ü., Jaal, J., & Uusküla, A. (2026). Nationwide Study on the Cervical Cancer Screening Pathway in Estonia. International Journal of Cancer, 159(4), 883-895. https://doi.org/10.1002/ijc.70466
Vancouver
Šavrova A, Jakoby H, Tisler A, Innos K, Maiväli Ü, Jaal J, et al. Nationwide Study on the Cervical Cancer Screening Pathway in Estonia. International Journal of Cancer. 2026;159(4):883-895. doi:10.1002/ijc.70466
BibTeX
@article{avrova2026,
author = {Šavrova, Aleksandra and Jakoby, Helen and Tisler, Anna and Innos, Kaire and Maiväli, Ülo and Jaal, Jana and Uusküla, Anneli},
title = {Nationwide Study on the Cervical Cancer Screening Pathway in Estonia},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {4},
pages = {883--895},
doi = {10.1002/ijc.70466}
}
EUVIMED